Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 549-560

  Thors, L ^a   Burston, J J ^b   Alter, B J ^c   McKinney, M K ^d   Cravatt, B F ^d   Ross, R A ^e   Pertwee, R G ^e   Gereau IV, R W ^c   Wiley, J L ^b   Fowler, C J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anandamide; Biochanin A; Cannabinoid; Fatty acid amide hydrolase; Isoflavones; Pain

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ANANDAMIDE; BIOCHANIN A; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DAIDZEIN; FATTY ACID AMIDASE; FORMONONETIN; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CANNABINOID RECEPTOR ANTAGONIST; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; ENDOCANNABINOID; FATTY-ACID AMIDE HYDROLASE; FORMALDEHYDE; ISOFLAVONE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; IC 50; IN VITRO STUDY; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BRAIN; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; METABOLISM; TRANSFORMED CELL LINE;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; BENZAMIDES; BRAIN; CANNABINOID RECEPTOR ANTAGONISTS; CARBAMATES; CELL LINE, TRANSFORMED; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG INTERACTIONS; ENDOCANNABINOIDS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FORMALDEHYDE; GENISTEIN; HUMANS; ISOFLAVONES; LIVER; MICE; MICE, INBRED ICR; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS;

EID: 77952613883     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00716.x     Document Type: Article

References (63)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Banerjee S, Li Y, Wang Z, Sarkar FH (2008). Multi-targeted therapy of cancer by genistein. Cancer Lett 269 : 226 242.
3. Basavarajappa BS, Yalamanchili R, Cravatt BF, Cooper TB, Hungund BL (2006). Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology 5 : 834 844.
4. Blednov YA, Cravatt BF, Boehm SL II., Walker D, Harris RA (2007). Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology 32 : 1570 1582.
5. Boldrup L, Wilson SJ, Barbier AJ, Fowler CJ (2004). A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Methods 60 : 171 177.
6. Booth NL, Piersen CE, Banuvar S, Geller SE, Shulman LP, Farnsworth NR (2006). Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: a literature review. Menopause 13 : 251 264.
7. Burston JJ, Sim-Selley LJ, Harloe JP, Mahadevan A, Razdan RK, Selley DE et al 2008). N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. J Pharmacol Exp Ther 327 : 546 553.
8. Calignano A, La Rana G, Piomelli D (2001). Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419 : 191 198.
9. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ et al 2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148 : 102 113. Corrigendum published in Br J Pharmacol 148: 114 (2006).
10. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF (2003). Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci 23 : 3916 3923.
11. Compton DR, Martin BR (1997). The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther 283 : 1138 1143.
12. Desroches J, Guindon J, Lambert C, Beaulieu P (2008). Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 155 : 913 924.
13. Eisenthal R, Cornish-Bowden A (1974). The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem J 139 : 715 720.
14. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC (2006). The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 120 : 581 588.
15. Fowler CJ, Naidu PS, Lichtman A, Onnis V (2009). The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or transient receptor potential vanilloid type 1. Br J Pharmacol 156 : 412 419.
16. Gao Y-J, Ji R-R (2009). c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury? Open Pain J 2 : 11 17.
17. Guindon J, De Léan A, Beaulieu P (2006). Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121 : 85 93.
18. Häbler C (1929). Über den K- und Ca-gehalt von eiter und exsudaten und seine beziehungen zum entzündungsschmerz. Klin Wochenschr 8 : 1569 1572.
19. Hardison S, Weintraub ST, Giuffrida A (2006). Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations. Prostaglandins Other Lipid Mediat 81 : 106 112.
20. Holt S, Comelli F, Costa B, Fowler CJ (2005). Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146 : 467 476.
21. Howes J, Waring M, Huang L, Howes LG (2002). Long-term pharmacokinetics of an extract of isoflavones from red clover (Trifolium pratense). J Altern Complement Med 8 : 135 142.
22. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147 : 281 288.
23. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26 : 13318 13327.
24. Ji R-R, Baba H, Brenner GJ, Woolf CJ (1999). Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 2 : 1114 1119.
25. Karim F, Wang CC, Gereau RW 4th. (2001). Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. J Neurosci 21 : 3771 3779.
26. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A et al 2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 : 76 78.
27. Kawasaki Y, Kohno T, Ji R-R (2006). Different effects of opioid and cannabinoid receptor agonists on C-fiber-induced extracellular signal-regulated kinase activation in dorsal horn neurons in normal and spinal nerve-ligated rats. J Pharmacol Exp Ther 316 : 601 607.
28. Khasabova IA, Khasabov SG, Harding-Rose C, Coicou LG, Seybold BA, Lindberg AE et al 2008). A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 28 : 11141 11152.
29. Kim H, Peterson TG, Barnes S (1998). Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 68 : 1418S 1425S.
30. + coordination tandem mass spectrometry. Anal Biochem 314 : 8 15.
31. Kurzer MS, Xu X (1997). Dietary phytoestrogens. Annu Rev Nutr 17 : 353 381.
32. Lam AN, Demasi M, James MJ, Husband AJ, Walker C (2004). Effect of red clover isoflavones on cox-2 activity in murine and human monocyte/macrophage cells. Nutr Cancer 49 : 89 93.
33. Lichtman AH, Leung D, Shelton C, Saghatelian A, Hardouin C, Boger D et al 2004a). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311 : 441 448.
34. Lichtman AH, Shelton CC, Advani T, Cravatt BF (2004b). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 : 319 327.
35. McFarland MJ, Porter AC, Rakhshan FR, Rawat DS, Gibbs RA, Barker EL (2004). A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. J Biol Chem 279 : 41991 41997.
36. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E et al 2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150 : 766 781.
37. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK et al 1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40 : 471 478.
38. Messina MJ, Wood CE (2008). Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 7 : 17.
39. Moon YJ, Sagawa K, Frederick K, Zhang S, Morris ME (2006). Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J 8 : E433 E442.
40. Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA (2002). Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 132 : 3168 3171.
41. Naidu PS, Booker L, Cravatt BF, Lichtman AH (2009). Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 329 : 48 56.
42. O'Sullivan SE (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152 : 576 582.
43. Pacher P, Bátkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 : 389 462.
44. Paylor B, Holt S, Fowler CJ (2006). The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol Res 54 : 481 485. Corrigendum published in Pharmacol Res 55: 80 (2007).
45. Pertwee RG (1972). The ring test: a quantitative method for assessing the 'cataleptic' effect of Cannabis in mice. Br J Pharmacol 46 : 753 763.
46. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63 : 569 611.
47. Ross RA (2003). Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 40 : 790 801.
48. 2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126 : 665 672.
49. Sagar DR, Kendall DA, Chapman V (2008). Inhibition of fatty acid amide hydrolase produces PPAR-α-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 155 : 1297 1306.
50. Seierstad M, Breitenbucher JG (2008). Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem 51 : 7327 7343.
51. Setchell KDR, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT et al 2001). Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131 : 1362S 1375S.
52. Shen P, Liu MH, Ng TY, Chan YH, Yong EL (2006). Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARα, PPARγ, and adipocyte differentiation in vitro. J Nutr 136 : 899 905.
53. Sirtori CR, Arnoldi A, Johnson SK (2005). Phytoestrogens: end of a tale? Ann Med 37 : 423 438.
54. Sit SY, Conway C, Bertekap R, Xie K, Bourin C, Burris K et al 2007). Novel inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 17 : 3287 3291.
55. 2 receptors in anaesthetised rats. Neuropharmacology 45 : 404 411.
56. 2 receptor antagonist. Br J Pharmacol 146 : 917 926.
57. Thors L, Fowler CJ (2009). Effect of nitric oxide donors on membrane tritium accumulation of endocannabinoids and related endogenous lipids. Eur J Pharmacol 621 : 10 18.
58. Thors L, Alajakku K, Fowler CJ (2007a). The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol 150 : 951 960.
59. Thors L, Eriksson J, Fowler CJ (2007b). Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake. Br J Pharmacol 152 : 744 750.
60. Thors L, Belghiti M, Fowler CJ (2008). Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids. Br J Pharmacol 155 : 244 252.
61. Tsai TH (2005). Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 1073 : 317 322.
62. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF (2006). A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 281 : 36569 36578.
63. Yueh T-L, Chu H-Y (1977). The metabolic fate of daidzein. Sci Sin 20 : 513 521.